Total Payments
$1.0M
2024 Payments
$142,230
Companies
16
Transactions
1,040
Medicare Patients
913
Medicare Billing
$472,651
Payment Breakdown by Category
Other$551,739 (53.1%)
Consulting$289,892 (27.9%)
Travel$138,287 (13.3%)
Research$41,977 (4.0%)
Food & Beverage$17,134 (1.6%)
Education$145.87 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $549,339 | 252 | 52.9% |
| Consulting Fee | $289,892 | 89 | 27.9% |
| Travel and Lodging | $138,287 | 356 | 13.3% |
| Unspecified | $41,977 | 12 | 4.0% |
| Food and Beverage | $17,134 | 324 | 1.6% |
| Honoraria | $2,400 | 1 | 0.2% |
| Education | $145.87 | 6 | 0.0% |
Payments by Type
General
$997,198
1,028 transactions
Research
$41,977
12 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| ABBVIE INC. | $423,265 | 525 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $202,741 | 143 | $0 (2024) |
| Janssen Scientific Affairs, LLC | $86,714 | 84 | $0 (2024) |
| Lilly USA, LLC | $79,237 | 82 | $0 (2024) |
| PFIZER INC. | $72,483 | 30 | $0 (2024) |
| UCB, Inc. | $36,681 | 43 | $0 (2024) |
| GENZYME CORPORATION | $34,123 | 41 | $0 (2022) |
| Eli Lilly and Company | $27,689 | 11 | $0 (2024) |
| Novartis Pharma AG | $25,574 | 15 | $0 (2022) |
| Janssen Biotech, Inc. | $25,312 | 27 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $142,230 | 114 | ABBVIE INC. ($47,239) |
| 2023 | $151,495 | 126 | AbbVie Inc. ($48,504) |
| 2022 | $257,989 | 271 | ABBVIE INC. ($136,895) |
| 2021 | $186,582 | 195 | AbbVie Inc. ($99,190) |
| 2020 | $88,567 | 54 | Novartis Pharmaceuticals Corporation ($48,496) |
| 2019 | $99,431 | 104 | Novartis Pharmaceuticals Corporation ($37,492) |
| 2018 | $28,504 | 53 | AbbVie, Inc. ($8,927) |
| 2017 | $84,378 | 123 | AbbVie, Inc. ($35,640) |
All Payment Transactions
1,040 individual payment records from CMS Open Payments — Page 1 of 42
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/17/2024 | ABBVIE INC. | RINVOQ (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,800.00 | General |
| Category: IMMUNOLOGY | ||||||
| 12/10/2024 | UCB, Inc. | Bimzelx (Biological) | Consulting Fee | Cash or cash equivalent | $2,850.00 | General |
| Category: Immunology | ||||||
| 12/04/2024 | Janssen Scientific Affairs, LLC | TREMFYA (Drug) | Consulting Fee | Cash or cash equivalent | $2,750.00 | General |
| Category: Immunology | ||||||
| 11/21/2024 | UCB, Inc. | Bimzelx (Biological) | Food and Beverage | In-kind items and services | $125.00 | General |
| Category: Immunology | ||||||
| 11/18/2024 | Janssen Scientific Affairs, LLC | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $149.26 | General |
| Category: Immunology | ||||||
| 11/18/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $31.46 | General |
| Category: Immunology | ||||||
| 11/18/2024 | Janssen Scientific Affairs, LLC | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $19.87 | General |
| Category: Immunology | ||||||
| 11/16/2024 | Novartis Pharmaceuticals Corporation | — | Food and Beverage | In-kind items and services | $130.13 | General |
| 11/12/2024 | UCB, Inc. | Bimzelx (Biological) | Consulting Fee | Cash or cash equivalent | $1,140.00 | General |
| Category: Immunology | ||||||
| 11/08/2024 | ABBVIE INC. | RINVOQ (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,200.00 | General |
| Category: IMMUNOLOGY | ||||||
| 10/29/2024 | Eli Lilly and Company | TALTZ (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $5,175.00 | General |
| Category: Immunology | ||||||
| 10/04/2024 | ABBVIE INC. | SKYRIZI (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,200.00 | General |
| Category: IMMUNOLOGY | ||||||
| 10/03/2024 | Eli Lilly and Company | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,025.00 | General |
| 10/03/2024 | Eli Lilly and Company | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,025.00 | General |
| 10/02/2024 | Lilly USA, LLC | TALTZ (Drug) | Consulting Fee | Cash or cash equivalent | $1,150.00 | General |
| Category: Immunology | ||||||
| 09/26/2024 | Eli Lilly and Company | — | Travel and Lodging | In-kind items and services | $477.99 | General |
| 09/26/2024 | Eli Lilly and Company | — | Travel and Lodging | In-kind items and services | $435.06 | General |
| 09/26/2024 | Eli Lilly and Company | — | Travel and Lodging | In-kind items and services | $148.00 | General |
| 09/26/2024 | Eli Lilly and Company | — | Travel and Lodging | In-kind items and services | $142.00 | General |
| 09/17/2024 | UCB, Inc. | Cimzia (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,425.00 | General |
| Category: Immunology | ||||||
| 09/11/2024 | Lilly USA, LLC | TALTZ (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $575.00 | General |
| Category: Immunology | ||||||
| 09/11/2024 | PFIZER INC. | XELJANZ (Drug) | Food and Beverage | In-kind items and services | $106.85 | General |
| Category: GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | ||||||
| 09/09/2024 | Novartis Pharmaceuticals Corporation | COSENTYX (Drug) | Consulting Fee | Cash or cash equivalent | $1,150.00 | General |
| Category: Dermatology | ||||||
| 08/13/2024 | UCB, Inc. | Bimzelx (Biological) | Consulting Fee | Cash or cash equivalent | $2,280.00 | General |
| Category: Immunology | ||||||
| 07/31/2024 | E.R. Squibb & Sons, L.L.C. | — | Consulting Fee | Cash or cash equivalent | $2,240.00 | General |
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| RESEARCH RELATED PUBLICATION SUPPORT | NOVARTIS PHARMACEUTICALS CORPORATION | $14,012 | 3 |
| RESEARCH RELATED PUBLICATIONS SUPPORT | Novartis Pharmaceuticals Corporation | $9,623 | 3 |
| RESEARCH RELATED PUBLICATIONS SUPPORT | NOVARTIS PHARMACEUTICALS CORPORATION | $8,622 | 2 |
| ADALIMUMAB PFIZER CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $3,200 | 1 |
| PUBLICATION SUPPORT PROVIDED IN CONNECTION WITH HEOR RESEARCH | NOVARTIS PHARMACEUTICALS CORPORATION | $2,415 | 1 |
| A RANDOMIZED DOUBLE BLIND ACTIVE CONTROL MULTICENTER STUDY TO EVALUATE THE EFFICACY AT WEEK 52 OF SUBCUTANEOUSLY ADMINISTERED SECUKINUMAB MONOTHERAPY COMPARED WITH SUBCUTANEOUSLY ADMINISTERED ADALIMUMAB MONOTHERAPY IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS | Novartis Pharmaceuticals Corporation | $2,205 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 9 | 256 | 6,629 | $481,299 | $193,482 |
| 2022 | 10 | 280 | 5,368 | $340,941 | $180,682 |
| 2021 | 7 | 199 | 2,042 | $108,202 | $53,571 |
| 2020 | 7 | 178 | 1,707 | $103,923 | $44,915 |
Total Patients
913
Total Services
15,746
Medicare Billing
$472,651
Procedure Codes
33
All Medicare Procedures & Services
33 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| Q5104 | Injection, infliximab-abda, biosimilar, (renflexis), 10 mg | Office | 2023 | 14 | 4,160 | $294,528 | $123,428 | 41.9% |
| J0897 | Injection, denosumab, 1 mg | Office | 2023 | 19 | 1,740 | $82,140 | $31,818 | 38.7% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 82 | 147 | $29,967 | $11,877 | 39.6% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 47 | 83 | $23,621 | $10,173 | 43.1% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2023 | 19 | 91 | $29,221 | $8,771 | 30.0% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2023 | 22 | 101 | $12,625 | $4,696 | 37.2% |
| 96415 | Administration of chemotherapy into vein, each additional hour | Office | 2023 | 19 | 108 | $7,440 | $2,268 | 30.5% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 17 | 29 | $1,247 | $308.85 | 24.8% |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | Office | 2023 | 17 | 170 | $510.00 | $143.01 | 28.0% |
| Q5104 | Injection, infliximab-abda, biosimilar, (renflexis), 10 mg | Office | 2022 | 13 | 2,760 | $184,604 | $109,353 | 59.2% |
| J0897 | Injection, denosumab, 1 mg | Office | 2022 | 17 | 1,800 | $55,800 | $30,467 | 54.6% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 81 | 149 | $26,139 | $12,274 | 47.0% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 47 | 73 | $17,746 | $9,323 | 52.5% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2022 | 19 | 82 | $24,450 | $8,158 | 33.4% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2022 | 25 | 106 | $13,154 | $5,369 | 40.8% |
| 20611 | Aspiration and/or injection of fluid large joint using ultrasound guidance | Office | 2022 | 14 | 43 | $8,944 | $2,714 | 30.3% |
| 96415 | Administration of chemotherapy into vein, each additional hour | Office | 2022 | 19 | 106 | $6,917 | $2,193 | 31.7% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2022 | 23 | 61 | $2,623 | $665.35 | 25.4% |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | Office | 2022 | 22 | 188 | $564.00 | $166.15 | 29.5% |
| J0897 | Injection, denosumab, 1 mg | Office | 2021 | 17 | 1,620 | $50,220 | $26,288 | 52.3% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 76 | 148 | $25,308 | $12,997 | 51.4% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 38 | 53 | $12,296 | $6,585 | 53.6% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis up to 1 hour | Office | 2021 | 15 | 80 | $9,760 | $4,358 | 44.6% |
| 20611 | Aspiration and/or injection of major joint or joint capsule with recording and reporting using ultrasound guidance | Office | 2021 | 15 | 36 | $7,488 | $2,482 | 33.2% |
| 96372 | Injection beneath the skin or into muscle for therapy, diagnosis, or prevention | Office | 2021 | 19 | 64 | $2,752 | $695.68 | 25.3% |
About Dr. Catherine Bakewell, M.D
Dr. Catherine Bakewell, M.D is a Internal Medicine healthcare provider based in Salt Lake City, Utah. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 08/13/2006. The National Provider Identifier (NPI) number assigned to this provider is 1336151786.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Catherine Bakewell, M.D has received a total of $1.0M in payments from pharmaceutical and medical device companies, with $142,230 received in 2024. These payments were reported across 1,040 transactions from 16 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($549,339).
As a Medicare-enrolled provider, Bakewell has provided services to 913 Medicare beneficiaries, totaling 15,746 services with total Medicare billing of $472,651. Data is available for 4 years (2020–2023), covering 33 distinct procedure/service records.
Ad
Practice Information
- Specialty Internal Medicine
- Other Specialties Rheumatology, Rheumatology
- Location Salt Lake City, UT
- Active Since 08/13/2006
- Last Updated 11/08/2013
- Taxonomy Code 207R00000X
- Entity Type Individual
- NPI Number 1336151786
Products in Payments
- RINVOQ (Biological) $259,766
- COSENTYX (Biological) $181,696
- TALTZ (Drug) $69,368
- SIMPONI ARIA (Biological) $59,988
- XELJANZ (Drug) $54,072
- TREMFYA (Drug) $52,028
- SKYRIZI (Biological) $37,632
- Humira (Biological) $24,140
- Cimzia (Drug) $21,513
- COSENTYX (Drug) $19,783
- RINVOQ (Drug) $19,187
- AIN457F_COSENTYX_IMMUNOLOGY (Biological) $18,369
- KEVZARA (Biological) $18,245
- KEVZARA SARILUMAB INJECTION (Biological) $16,620
- Rinvoq (Biological) $11,878
- KEVZARA (Drug) $10,678
- Bimzelx (Biological) $6,416
- NO PRODUCT DISCUSSED (Drug) $5,974
- ABRILADA (Biological) $4,800
- HUMIRA (Biological) $1,425
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Internal Medicine Doctors in Salt Lake City
Dr. Willard Dere, M.d, M.D
Internal Medicine — Payments: $5.4M
Internal Medicine $5.4M
Dr. April Erwin, Md, MD
Internal Medicine — Payments: $381,757
Internal Medicine $381,757
Dr. Neeraj Agarwal, Md, MD
Internal Medicine — Payments: $344,790
Internal Medicine $344,790
George Rodgers, M.d, M.D
Internal Medicine — Payments: $229,629
Internal Medicine $229,629
James Chamberlain, Md, MD
Internal Medicine — Payments: $200,257
Internal Medicine $200,257
Schickwann Tsai, M.d, M.D
Internal Medicine — Payments: $122,681
Internal Medicine $122,681